Lataa...
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the...
Tallennettuna:
| Julkaisussa: | Front Oncol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4295550/ https://ncbi.nlm.nih.gov/pubmed/25642417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00385 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|